A Clinical Trial of Antiplatelets in Psoriasis

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT07744191
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Psoriasis (PsO)
  • Psoriatic Arthritis (PsA)

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Aspirin — DRUG
    81 mg capsule orally once daily for 4 weeks
  • Clopidogrel — DRUG
    75 mg capsule orally once daily for 4 weeks
  • Placebo — OTHER
    Matching placebo (microcellulose powder) capsule orally once daily for 4 weeks

Study Details

The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.

Key Dates

First listed
Aug 4, 2026
Start date
Sep 30, 2026
Status verified
Jul 2026
Primary completion
Sep 30, 2031
Completion
Sep 30, 2031

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Aspirin, then Clopidogrel, then Placebo
    Each subject will take an aspirin 81mg capsule daily for 4 weeks. After a washout period of 4 weeks, they will take the clopidogrel 75mg capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take the Placebo capsule daily for 4 weeks.
  • Experimental: Aspirin, then Placebo, then Clopidogrel
    Each subject will take an aspirin 81mg capsule daily for 4 weeks. After a washout period of 4 weeks, they will take the Placebo capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take the clopidogrel 75mg capsule daily for 4 weeks.
  • Experimental: Clopidogrel, then Aspirin, then Placebo
    Each subject will take will take the clopidogrel 75mg capsule daily for 4 weeks. After a washout period of 4 weeks, they will take an aspirin 81mg capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take the Placebo capsule daily for 4 weeks.
  • Experimental: Clopidogrel, then Placebo, then Aspirin
    Each subject will take will take the clopidogrel 75mg capsule daily for 4 weeks. After a washout period of 4 weeks, they will take the Placebo capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take an aspirin 81mg capsule daily for 4 weeks.
  • Experimental: Placebo, then Aspirin, then Clopidogrel
    Each subject will take will take the Placebo capsule daily for 4 weeks. After a washout period of 4 weeks, they will take an aspirin 81mg capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take the clopidogrel 75mg capsule daily for 4 weeks.
  • Experimental: Placebo, then Clopidogrel, then Aspirin
    Each subject will take will take the Placebo capsule daily for 4 weeks. After a washout period of 4 weeks, they will take the clopidogrel 75mg capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take an aspirin 81mg capsule daily for 4 weeks.

Primary Outcome Measure

Mean change in the composite endothelial pro-inflammatory transcript expression [ Time Frame: Baseline, Follow-up Visit 1 (Week 4) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By research site
NYU Langone Health· New York, NY

Related Studies